Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Nivolumab Combined With Ipilimumab in Melanoma Brain Metastases
NCT02374242Phase 2Active, not recruiting
- Sponsor
- Melanoma Institute Australia
- Start
- Nov 2014
- Primary completion
- Sep 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nivolumab and ipilimumab in melanoma brain metastases (MBM) (3 cohorts), sponsored by Melanoma Institute Australia. Primary endpoint: Intracranial response rate at 3 years. Started Nov 2014; status: active, not recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
melanoma brain metastases (MBM)
Beyond the preview
Go deeper on NCT02374242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02374242.